Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Provided By GlobeNewswire
Last update: Mar 26, 2025
SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024.
Read more at globenewswire.com
